NDC product
Robitussin Direct Cough
NDC 0031-9302 · Haleon US Holdings LLC
Key facts
| Product NDC | 0031-9302 |
|---|---|
| Proprietary name | Robitussin Direct Cough |
| Nonproprietary name | dextromethorphan hydrobromide |
| Substances | DEXTROMETHORPHAN HYDROBROMIDE |
| Dosage form | CAPSULE, LIQUID FILLED |
| Route | ORAL |
| Labeler | Haleon US Holdings LLC |
| Product type | HUMAN OTC DRUG |
| Marketing category | OTC MONOGRAPH DRUG |
| Application number | M012 |
| Pharmacologic classes | Sigma-1 Agonist [EPC], Sigma-1 Receptor Agonists [MoA], Uncompetitive N-methyl-D-aspartate Receptor Antagonist [EPC], Uncompetitive NMDA Receptor Antagonists [MoA] |
| Marketing start | Jul 15, 2022 |
| Listing certified through | Dec 31, 2027 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory · Source date: